Agilent’s PD-L1 IHC 22C3 pharmDx Assay Approved for TNBC use in EU
Agilent’s PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying Triple-Negative Breast Cancer (TNBC) patients for
Read more
Latest
First Evotec-BMS Academic BRIDGE Collaboration Projects to Focus on Oncology
The first two projects funded within the translational BRIDGE beLAB1407 collaboration will focus on new mechanisms to treat cancer, Evotec
Read more
FDA Panel in Favor of Pfizer’s COVID-19 Vaccine for Children Aged 5 to 12
The U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) has voted 17 to 0,
Read more
Valneva’s COVID-19 Vaccine Candidate Shows Positive Results in Phase 3 Trial
French pharmaceutical company Valneva has reported positive results for its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001 in the Phase 3
Read more
FDA Expands Use of COVID-19 Vaccine Booster Dose in Eligible Populations
The US Food and Drug Administration has granted approval for administration of COVID-19 vaccine booster dosage, upgrading the emergency use
Read more
GSK Reveals Plan for Consumer Healthcare Company UK-based HQ
GSK revealed ideas for a large new UK-based headquarters and global campus for the new Consumer Healthcare company, after the
Read more
Genentech’s Investigational Antibody Wins BTD for Alzheimer’s Treatment
Genentech’s investigational antibody for the treatment of early-stage Alzheimer’s disease, Gantenerumab, has been granted Breakthrough Therapy Designation by the U.S.
Read more
Tezepelumab gets ODD in the US for Eosinophilic Esophagitis
Tezepelumab, developed by AstraZeneca in collaboration with Amgen, has been granted Orphan Drug Designation (ODD) in the US FDA for
Read more
WHO Endorses GlaxoSmithKline’s Breakthrough Malaria Vaccine
The World Health Organization on Wednesday endorsed the groundbreaking GlaxoSmithKline Malaria vaccine for children at risk reinvigorating the fight against
Read more
Merck and Ridgeback’s Oral Antiviral Molnupiravir Can Halve COVID-19 Risk of Hospitalisation
Interim Analysis of Phase 3 Study shows Merck and Ridgeback’s investigational oral antiviral Molnupiravir has reduced the risk of hospitalization
Read more